Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 5/20 | 0.48 |
| ▸ | FEN1 | P39748 | 5/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38655985 | 0.78 | DHFR (0.51) | KDM4EHPGDPKMERCC1FEN1 | |
| SCHEMBL17060210 | 0.76 | FGFR1 (0.59) | NOS1KDM4EHPGDALDH1A1GLA | |
| SCHEMBL26968497 | 0.75 | ADORA3 (0.62) | KDM4EHPGDPKMERCC1FEN1 | |
| SCHEMBL41999 | 0.74 | ADORA3 (0.49) | NOS1KDM4EHPGDPKMERCC1 | |
| Hydrochloric Acid SCHEMBL1895412 | 0.72 | ADORA3 (0.48) | NOS1KDM4EHPGDPKMERCC1 | |
| 8-Aminoguanine SCHEMBL21760 | 0.70 | KDM4E (0.60) | KDM4EPKMALDH1A1GLAMAPT | |
| SCHEMBL26968368 | 0.70 | ADORA3 (0.48) | KDM4EHPGDPKMERCC1FEN1 | |
| SCHEMBL26968714 | 0.69 | KDM4E (0.47) | KDM4EHPGDPKMERCC1FEN1 | |
| SCHEMBL29108569 | 0.68 | ADORA3 (0.43) | KDM4EHPGDPKMERCC1FEN1 | |
| SCHEMBL9253425 | 0.68 | ADORA2B (0.59) | KDM4EHPGDPKMERCC1FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1889 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| US-11939582-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | ROGCON, INC. (US) | 2024-03-26 | — | — | US | claimed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023192885-A2 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023150716-A2 | METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2022-05-12 | — | — | US | claimed |
| US-11186849-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-30 | — | — | US | claimed |
| US-20090275133-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-7223849-B1 | Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth | GENESENSE TECHNOLOGIES INC. (CA) | 2007-05-29 | — | — | US | claimed |
| US-7087580-B2 | Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth | GENESENSE TECHNOLOGIES, INC. (CA) | 2006-08-08 | — | — | US | claimed |
| US-7067497-B2 | Modulation of telomere length by oligonucleotides having a G-core sequence | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-20060024727-A1 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | claimed |
| EP-1153128-B1 | ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF RIBONUCLEOTIDE REDUCTASE | GENESENSE TECHNOLOGIES INC (CA) | 2005-11-09 | — | — | EP | claimed |
| EP-0917569-B1 | ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF RIBONUCLEOTIDE REDUCTASE | GENESENSE TECHNOLOGIES INC (CA) | 2005-11-09 | — | — | EP | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |
| WO-2004011613-A2 | COMPOSITION & METHODS FOR TREATMENT AND SCREENING | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| US-6566514-B1 | Antisense oligonucleotides for use in the treatment of tumors | GENESENSE TECHNOLOGIES INC. (CA) | 2003-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | NOS1 2262/4885KDM4E 4454/4885HPGD 4222/4885 |
| US-11939582-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | SCN1A, SCN2A, SCN1B | NOS1 3239/4885KDM4E 2558/4885HPGD 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.